1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 What Is This Report About? 6
2.2 Electrophysiology Devices Market Segmentation 6
2.3 Definitions of Markets Covered in the Report 7
3 Electrophysiology Devices Market, United States 9
3.1 Electrophysiology Devices Market, United States, Revenue ($m), 2015-2025 9
3.1.1 Electrophysiology Ablation Catheters Market, United States, Revenue ($m), by Segment, 2015-2025 11
3.1.2 Electrophysiology Diagnostic Catheters Market, United States, Revenue ($m), by Segment, 2015-2025 13
3.1.3 Electrophysiology Lab Systems Market, United States, Revenue ($m), by Segment, 2015-2025 15
3.2 Electrophysiology Devices Market, United States, Volume (Units), 2015-2025 18
3.2.1 Electrophysiology Ablation Catheters Market, United States, Volume (Units), by Segment, 2015-2025 20
3.2.2 Electrophysiology Diagnostic Catheters Market, United States, Volume (Units), by Segment, 2015-2025 22
3.2.3 Electrophysiology Lab Systems Market, United States, Volume (Units), by Segment, 2015-2025 24
3.3 Electrophysiology Devices Market, United States, Average Price ($), 2015-2025 27
3.4 Electrophysiology Devices Market, United States, Distribution Share by Revenue ($m), 2019 29
3.5 Electrophysiology Devices Market, United States, Company Share by Revenue ($m), 2019 30
4 Overview of Key Companies in United States, Electrophysiology Devices Market 32
4.1 Biosense Webster Inc 32
4.1.1 Company Overview 32
4.2 Abbott Laboratories 32
4.2.1 Company Overview 32
4.3 Medtronic Plc 32
4.3.1 Company Overview 32
4.4 Boston Scientific Corp 33
4.4.1 Company Overview 33
4.5 GE Healthcare LLC 33
4.5.1 Company Overview 33
4.6 Koninklijke Philips NV 33
4.6.1 Company Overview 33
5 Electrophysiology Devices Market Pipeline Products 34
6 Financial Deals Landscape 35
6.1 Acquisition 35
6.1.1 Siemens Healthineers Acquires Corindus Vascular Robotics 35
6.2 Debt Offerings 37
6.2.1 Boston Scientific Raises USD1.2 Billion in Public Offering of
2.65% Senior Notes due 2030 37
6.2.2 Boston Scientific Raises USD500 Million in Public Offering of
1.9% Senior Notes due 2025 39
6.2.3 Boston Scientific Raises USD999.2 Million in Public Offering of
0.625% Notes Due 2027 41
6.3 Equity Offerings 43
6.3.1 Boston Scientific Raises USD1 Billion in Public Offering of Shares 43
6.3.2 Boston Scientific Raises USD1 Billion in Public Offering of
5.5% Mandatory Convertible Preferred Stock 45
6.3.3 AtriCure Prices Public Offering of Shares for USD175 Million 47
6.3.4 Stereotaxis Files Registration Statement for Public Offering of Securities for up to USD100 Million 49
6.3.5 Imricor Medical Systems Raises USD13.5 Million in Private Placement of Shares 50
6.3.6 Imricor Medical Systems Plans to Raise USD0.3 Million in Private Placement of Shares 52
6.3.7 Stereotaxis Raises USD25 Million in Private Placement of Common Stock 53
6.4 Private Equity 55
6.4.1 Stereotaxis to Raise USD15 Million in Private Placement of Shares 55
6.5 Venture Financing 56
6.5.1 NeuroClear Technologies Raises USD3.7 Million in Seed Funding 56
6.5.2 Imricor Medical Systems Raises USD0.6 Million in Venture Financing 57
7 Recent Developments 58
7.1 Corporate Communications 58
7.1.1 Dec 23, 2019: Mayo Clinic names chief digital officer to lead transformative digital strategy, create Center for Digital Health 58
7.1.2 Dec 04, 2019: AtriCure names two industry veterans to Board of Directors 58
7.1.3 Dec 03, 2019: Dr. John Halamka named president of Mayo Clinic Platform 59
7.1.4 Oct 31, 2019: Harvard Bioscience Announces Executive Appointment 60
7.1.5 Oct 21, 2019: Harvard Bioscience announces Executive appointment 60
7.1.6 Sep 16, 2019: Stereotaxis announces CFO transition 60
7.1.7 Sep 04, 2019: Harvard Bioscience elects Alan Edrick to Board of Directors 61
7.1.8 Aug 19, 2019: Merit Medical announces appointment of Lynne N. Ward to its Board of Directors 61
7.1.9 Jul 24, 2019: Former Medtronic Executive Sean Ginney named VP of Sales at Current Health 62
7.1.10 Jul 18, 2019: Harvard Bioscience names Michael Rossi Chief Financial Officer 62
7.1.11 Jul 08, 2019: James Green named President and CEO of Harvard Bioscience 63
7.2 Financial Announcements 63
7.2.1 Feb 26, 2020: Harvard Bioscience announces fourth quarter 2019 financial results 63
7.2.2 Feb 24, 2020: Merit Medical reports earnings for fourth quarter and year ended December 31, 2019, gives FY 2020 Guidance 65
7.2.3 Feb 20, 2020: Integer Holdings reports results for fourth quarter and full year 2019 66
7.2.4 Feb 05, 2020: Boston Scientific announces results for fourth quarter and full year 2019 67
7.2.5 Jan 14, 2020: Boston Scientific announces preliminary unaudited sales for the fourth quarter and full year 2019 69
7.2.6 Nov 14, 2019: Stereotaxis reports 2019 third quarter financial results 70
7.2.7 Nov 05, 2019: Harvard Bioscience announces third quarter financial results 71
7.2.8 Oct 30, 2019: Merit Medical reports earnings for third quarter of 2019 72
7.2.9 Oct 30, 2019: AtriCure reports third quarter 2019 financial results 75
7.2.10 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 76
7.2.11 Aug 08, 2019: Corindus reports second quarter 2019 results 77
7.2.12 Aug 08, 2019: Stereotaxis reports 2019 second quarter financial results 78
7.2.13 Aug 01, 2019: Integer Holdings reports second quarter 2019 results 79
7.2.14 Jul 30, 2019: AtriCure reports second quarter 2019 Financial Results 80
7.2.15 Jul 25, 2019: Merit Medical reports earnings for second quarter of 2019 80
7.2.16 Jul 25, 2019: Harvard Bioscience announces quarter ended June 30, 2019 financial results 83
7.2.17 Jul 24, 2019: Boston Scientific announces results for second quarter 2019 84
7.3 Government and Public Interest 85
7.3.1 Jan 27, 2020: Merit Medical issues statement regarding director nominations from starboard 85
7.4 Legal And Regulatory 86
7.4.1 Jan 23, 2020: Vulnerability disclosure regarding GE Healthcare monitoring products 86
7.4.2 Nov 18, 2019: Integer updates 2019 guidance following customer chapter 11 filing, no change in prior view of 2020 sales outlook 87
7.5 Other Significant Developments 88
7.5.1 Apr 14, 2020: BioCardia announces litigation financing in the case captioned Boston Scientific 88
7.5.2 Nov 12, 2019: Integer announces commitments to reprice and extend maturity of its revolving credit facility and term Loan A; launches term Loan B repricing 89
7.5.3 Nov 01, 2019: Stereotaxis and ADAS 3D combine robotic precision and advanced preoperative substrate mapping to treat cardiac arrhythmias 89
7.5.4 Sep 09, 2019: Harvard Bioscience announces strategic action plan and financial targets 90
7.5.5 Aug 28, 2019: Boston Scientific Celebrates 15th Anniversary in Costa Rica 90
7.5.6 Jul 10, 2019: Medtronic announces the early results of its cash tender offers for up to $5.525 billion of certain outstanding debt securities 91
7.6 Product News 92
7.6.1 Dec 09, 2019: Porton Biopharma – Erwinase manufacturing schedule 92
7.6.2 Nov 22, 2019: Stereotaxis CEO to present at the 12th Annual BIOMEDevice San Jose Conference 92
7.6.3 Nov 15, 2019: OncoTherapy Science: Publication of a paper describing the anti-cancer effect of TOPK inhibitor OTS514 on multiple myeloma 93
7.6.4 Nov 11, 2019: EMist to reveal a breakthrough disinfectant sprayer 93
7.7 Strategy And Business Planning 94
7.7.1 Jun 25, 2020: Integer Opens New Innovative Ireland Research and Development Facility 94
7.7.2 Feb 20, 2020: Integer acquires Israel-based medical device firm Inomec 94
7.7.3 Jan 15, 2020: Merit milestones: facilities in Galway and Tijuana reach 1,000 employees 95
8 Appendix 96
8.1 Research Methodology 97
8.1.1 Coverage 97
8.1.2 Secondary Research 97
8.1.3 Primary Research 98
8.1.4 Market Modeling and Forecasting 99
8.1.5 Company Share Analysis 101
8.1.6 Distribution Share Analysis 101
8.1.7 Benchmarking 101
8.2 GlobalData Consulting 102
8.3 Contact Us 102
8.4 Disclaimer 103
